alprostadil - CISMeF

Preferred Label : alprostadil;

MeSH definition : A potent vasodilator agent that increases peripheral blood flow.;

MeSH synonym : lipo-pge1; pge1alpha; prostaglandin e1alpha; pge1; lipo pge1; prostaglandin e1;

CISMeF synonym : AstraZeneca brand of alprostadil; abbott brand of alprostadil; allphar brand of alprostadil; astra brand of alprostadil; hoyer brand of alprostadil; janssen brand of alprostadil; paladin brand of alprostadil; pharmacia brand 1 of alprostadil; pharmacia brand 2 of alprostadil; schwarz brand of alprostadil; schwarz pharma brand of alprostadil; vivus brand of alprostadil; viridal; minprog; sugiran;

DeCS synonym : Minprog; Viridal; Sugiran;

MeSH hyponym : prostine vr; vasaprostan; prostin VR; muse; caverject; edex; Prostavasin;

MeSH CAS label : Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-;

MeSH Related Number : 745-65-3 (Alprostadil);

Registry Number MeSH : 745-65-3;

Wikipedia link : https://en.wikipedia.org/wiki/Prostaglandin E1;

Codes EINECS : 212-017-2;

Is substance : O;

UNII : F5TD010360;

InChIKey : GMVPRGQOIOIIMI-DWKJAMRDSA-N;

Details

Origin ID

D000527;

UMLS CUI

C0002335;

ATC code(s)
- alprostadil [ATC Code]
- alprostadil [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Alprostadil adverse reaction (disorder) [SNOMED CT concept]
- alprostadil [Substance BNPC]
Currated CISMeF NLP mapping
- Alprostadil [ICD-11 Extension code]
- Alprostadil [NCIt concept]
- Alprostadil (substance) [SNOMED CT concept]
- Prostaglandin E1 [ICD-11 Extension code]
- Prostaglandin E1 [LOINC component]
- prostaglandin pge1 [SNOMED Notion]
Pharmacological action(s)
- platelet aggregation inhibitors [MeSH Descriptor]
- urological agents [MeSH Descriptor]
- vasodilator agents [MeSH Descriptor]
Record concept(s)
- Minprog [MeSH concept]
- Sugiran [MeSH concept]
- Viridal [MeSH concept]
- alprostadil [MeSH concept]
- caverject [MeSH concept]
- edex [MeSH concept]
- muse [MeSH concept]
- prostin VR [MeSH concept]
- vasaprostan [MeSH concept]
Related MeSH Supplementary Concept(s)
- 11,15-bisdeoxyprostaglandin E1 [MeSH Supplementary Concept]
- 11-deoxy-10-hydroxyprostaglandin E1 methyl ester [MeSH Supplementary Concept]
- 11-deoxy-13,14-dihydro-8-azaprostaglandin E(1) [MeSH Supplementary Concept]
- 11-deoxy-16,16-trimethyleneprostaglandin E1 [MeSH Supplementary Concept]
- 11-deoxy-16-phenoxy-17,18,19,20-tetranorprostaglandin E1 [MeSH Supplementary Concept]
- 11-deoxy-4,4-dimethyl-4-silaprostaglandin E1 [MeSH Supplementary Concept]
- 11-deoxy-8-azaprostaglandin E(1) [MeSH Supplementary Concept]
- 11-deoxyprostaglandin E1 [MeSH Supplementary Concept]
- 11-deoxyprostaglandin E1 4-hydroxyphenyl ester [MeSH Supplementary Concept]
- 13,14-dihydro-15-ketoprostaglandin E1 [MeSH Supplementary Concept]
- 13,14-dihydroprostaglandin E1 [MeSH Supplementary Concept]
- 15(S)-15-methylprostaglandin E1 [MeSH Supplementary Concept]
- 15-cyclohexyl-omega-pentanor-7-thiaprostaglandin E1 [MeSH Supplementary Concept]
- 15-fluoro-11,15-dideoxyprostaglandin E1 [MeSH Supplementary Concept]
- 15-keto-13,14-dihydro-6-ketoprostaglandin E1 [MeSH Supplementary Concept]
- 15-keto-prostaglandin E0 [MeSH Supplementary Concept]
- 15-ketoprostaglandin E [MeSH Supplementary Concept]
- 16,16-dimethyl-delta2-prostaglandin E1 [MeSH Supplementary Concept]
- 16,18-ethano 20-ethyl-6-oxoprostaglandin E1 [MeSH Supplementary Concept]
- 16,18-ethano-20-ethyl-6-oxoprostaglandin E1 leucinamide [MeSH Supplementary Concept]
- 17,18,19,20-tetranor-16-(3-biphenyl)-2,3,13,14-tetradehydroprostaglandin E1 [MeSH Supplementary Concept]
- 17,18-dehydroprostaglandin E1 [MeSH Supplementary Concept]
- 18-hydroxyprostaglandin E1 [MeSH Supplementary Concept]
- 19-hydroxyprostaglandin E1 [MeSH Supplementary Concept]
- 20-dimethyl-7-thiaprostaglandin E1 methyl ester [MeSH Supplementary Concept]
- 20-hydroxyprostaglandin E1 [MeSH Supplementary Concept]
- 3,7-dithia(11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid [MeSH Supplementary Concept]
- 3-oxa-4,5,6-nor-(3,7-inter)-3-phenyleneprostaglandin E1 methyl ester [MeSH Supplementary Concept]
- 3-oxa-4,5,6-nor-3,7-inter-3-phenyleneprostaglandin E1 [MeSH Supplementary Concept]
- 3-oxa-4,5,6-trinor-3,7-inter-3-phenyleneprostaglandin E1 amide [MeSH Supplementary Concept]
- 4-thiaprostaglandin E1 [MeSH Supplementary Concept]
- 5(6)-epoxyprostaglandin E1 alpha [MeSH Supplementary Concept]
- 5,6-dihydroxyprostaglandin E1 [MeSH Supplementary Concept]
- 6-ketoprostaglandin E1 [MeSH Supplementary Concept]
- 7-keto-9,9-ethylenedioxiprostanoid [MeSH Supplementary Concept]
- 7-oxo-15-methylprostaglandin E1 methyl ester [MeSH Supplementary Concept]
- 8-azaprostaglandin E1 [MeSH Supplementary Concept]
- AY 23626 [MeSH Supplementary Concept]
- MR 356 [MeSH Supplementary Concept]
- NP 01A [MeSH Supplementary Concept]
- NP 07 A [MeSH Supplementary Concept]
- NP 13 A [MeSH Supplementary Concept]
- ONO 1082 [MeSH Supplementary Concept]
- ONO 1206 [MeSH Supplementary Concept]
- ONO-DI-004 [MeSH Supplementary Concept]
- SC 29169 [MeSH Supplementary Concept]
- SC 31391 [MeSH Supplementary Concept]
- SC-46275 [MeSH Supplementary Concept]
- SPM 206 [MeSH Supplementary Concept]
- TFC 612 [MeSH Supplementary Concept]
- TR4161 [MeSH Supplementary Concept]
- alprostadil, prazosin drug combination [MeSH Supplementary Concept]
- butaprost [MeSH Supplementary Concept]
- delta-17-tetranorprostaglandin E1 [MeSH Supplementary Concept]
- enisoprost [MeSH Supplementary Concept]
- gemeprost [MeSH Supplementary Concept]
- isoprostaglandin E1 [MeSH Supplementary Concept]
- limaprost [MeSH Supplementary Concept]
- limaprost-alfadex [MeSH Supplementary Concept]
- mexiprostil [MeSH Supplementary Concept]
- ornoprostil [MeSH Supplementary Concept]
- prostaglandin E0 [MeSH Supplementary Concept]
- prostaglandin E1 ethyl ester [MeSH Supplementary Concept]
- prostaglandin E1 methyl ester [MeSH Supplementary Concept]
- prostaglandin E1-alpha-cyclodextrin [MeSH Supplementary Concept]
- prostaglandin E1-hexyl-sepharose [MeSH Supplementary Concept]
- prostaglandin E3 [MeSH Supplementary Concept]
- tetranorprostaglandin E1 [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing alprostadil (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Alprostadil [ICD-11 Extension code]
- Alprostadil [NCIt concept]
- Alprostadil (substance) [SNOMED CT concept]
- Product containing alprostadil (medicinal product) [SNOMED CT concept]
- Prostaglandin E1 [ICD-11 Extension code]
- Prostaglandin E1 [LOINC component]
- Prostaglandin E>1< preparation (product) [Inactive SNOMED CT concept]
- alprostadil [ATC Code]
- alprostadil [ATC Code]
- alprostadil [Substance BNPC]
- prostaglandin pge1 [SNOMED Notion]
Validated automatic mappings to BTNT
- alprostadil [ATC Code]
- alprostadil [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients